| Secondary |
| Rheumatoid Arthritis |
14.1% |
| Product Used For Unknown Indication |
12.7% |
| Drug Use For Unknown Indication |
11.4% |
| Langerhans' Cell Histiocytosis |
11.4% |
| Crohn's Disease |
5.7% |
| Scleroderma |
4.9% |
| Premedication |
4.3% |
| Sinusitis |
4.3% |
| Anxiety |
4.1% |
| Pruritus |
4.1% |
| Rash Generalised |
4.1% |
| Arthralgia |
3.8% |
| Asthma |
3.0% |
| Immunosuppression |
2.4% |
| Antifungal Prophylaxis |
2.2% |
| Hypertension |
1.9% |
| Prophylaxis |
1.6% |
| Cryoglobulinaemia |
1.4% |
| Pemphigus |
1.4% |
| Pulmonary Tuberculosis |
1.4% |
|
| Pain |
21.1% |
| Hepatitis |
12.7% |
| Pyrexia |
8.5% |
| Visual Acuity Reduced |
5.6% |
| Arrhythmia |
4.2% |
| Metastases To Lung |
4.2% |
| Osteonecrosis |
4.2% |
| Respiratory Failure |
4.2% |
| Urinary Tract Infection |
4.2% |
| Hyponatraemia |
2.8% |
| Intestinal Ischaemia |
2.8% |
| Opisthotonus |
2.8% |
| Sepsis |
2.8% |
| Staphylococcal Sepsis |
2.8% |
| Tachypnoea |
2.8% |
| Tendonitis |
2.8% |
| Tremor |
2.8% |
| Vision Blurred |
2.8% |
| Visual Impairment |
2.8% |
| Weight Decreased |
2.8% |
|
| Concomitant |
| Premedication |
12.3% |
| Prophylaxis |
10.2% |
| Breast Cancer |
8.6% |
| Rheumatoid Arthritis |
8.0% |
| Idiopathic Thrombocytopenic Purpura |
7.9% |
| Uveitis |
7.2% |
| Product Used For Unknown Indication |
7.0% |
| Colorectal Cancer Metastatic |
6.2% |
| Crohn's Disease |
5.4% |
| Acne |
3.3% |
| Antiinflammatory Therapy |
2.8% |
| Diffuse Vasculitis |
2.8% |
| Non-small Cell Lung Cancer Stage Iv |
2.6% |
| Pancreatitis Acute |
2.5% |
| Hypertension |
2.4% |
| Chemotherapy |
2.4% |
| Drug Use For Unknown Indication |
2.2% |
| Non-small Cell Lung Cancer |
2.1% |
| Asthma |
1.9% |
| Psoriasis |
1.9% |
|
| Demyelination |
12.3% |
| Peripheral Sensory Neuropathy |
9.6% |
| Pneumonia |
7.5% |
| Death |
6.8% |
| Vomiting |
6.8% |
| Myalgia |
6.2% |
| Colitis Ulcerative |
5.5% |
| Pyrexia |
4.8% |
| Drug Ineffective |
4.1% |
| Herpes Zoster |
4.1% |
| Blood Fibrinogen Decreased |
3.4% |
| Cardiac Failure |
3.4% |
| Hepatosplenic T-cell Lymphoma |
3.4% |
| Neutropenia |
3.4% |
| Rash Erythematous |
3.4% |
| Sepsis |
3.4% |
| Tremor |
3.4% |
| General Physical Health Deterioration |
2.7% |
| Hypersensitivity |
2.7% |
| Infection |
2.7% |
|
| Interacting |
| Chronic Sinusitis |
60.0% |
| Drug Use For Unknown Indication |
30.0% |
| Acute Lymphocytic Leukaemia |
10.0% |
|
| Tendon Rupture |
42.9% |
| Drug Interaction |
28.6% |
| Presyncope |
28.6% |
|
